- A case study links daily use of cannabidiol (CBD) oil to regression of lung cancer in an octogenarian woman who refused conventional treatment.
- Researchers cannot definitively confirm that CBD oil caused tumor shrinkage.
- Further research is needed to define the mechanism of action, effects on different types of cancer, side effects, and optimal dosage and routes of administration.
Cannabinoids are chemical compounds
CBD and delta-9-tetrahydrocannabinol (THC) are the two main cannabinoids found in the cannabis plant. However, CBD does not produce the euphoric, or “high,” feeling that people associate with cannabis use.
CBD oil is a concentrated extract derived from cannabis leaves or flowers dissolved in an edible oil, such as olive, hemp, or sunflower oil. There are different types of CBD oil containing varying concentrations of cannabinoids.
CBD isolates contain CBD alone. Full spectrum CBD products contain compounds from all parts of the C. sativa plant, with less than 0.3% THC.
Broad-spectrum CBD products contain most of the same compounds as full-spectrum CBD products, but only trace amounts of THC.
Full-spectrum and broad-spectrum products can produce greater clinical effects than CBD isolates due to the entourage effect – the combination of cannabinoids has a more pronounced impact than individual isolates.
Cannabinoids interact with the body’s internal cannabinoid system, which experts call the endocannabinoid system. This system modulates:
Currently, some people with cancer may use cannabinoids for supportive care to treat chemotherapy-related pain and nausea and vomiting.
Doctors from the UK recently published an article in the journal BMJ Case reports. The case report describes an octogenarian woman with lung cancer who experienced tumor regression while taking CBD oil.
She also has a history of chronic obstructive pulmonary disease, high blood pressure and osteoarthritis and has received medication to treat these conditions.
The woman reported smoking just over a pack of cigarettes per week, or 68 packs per year, before and after diagnosis. In June and July 2018, doctors examined the woman, which included a CT scan, PET scan, MRI and biopsy, to stage and confirm the diagnosis.
The doctors made a diagnosis of
The tests did not reveal any involvement of the lymph nodes or metastases, which is when the cancer spreads to other parts of the body. For this reason, doctors recommended curative treatment.
Treatment for NSCLC may include surgery,
Doctors repeated the chest CT scan in September 2018, which showed a reduction in the right middle lobe cancer to 33 mm (1.3 in) and two new nodules in the left apex and right upper lobe.
The woman refused surgical removal of the lobe due to the risks of the surgery. She also refused radiofrequency ablation treatment because of the side effects her late husband had suffered from radiation therapy.
Doctors decided to monitor the patient by performing CT scans every 3-6 months. Over the 2.5-year follow-up period, CT scans showed a progressive decrease in the initial right middle lobe nodule from 41 mm (1.6 in) in June 2018 to 10 mm (0.4 in) in February 2021.
At that time, the woman revealed that she began taking CBD oil at a dose of 0.5 milliliters orally three times a day, and sometimes twice a day, shortly thereafter. his diagnosis.
The active ingredients specified by the supplier were THC (19.5%), CBD (20.05%) and tetrahydrocannabinolic acid (23.8%).
On the supplier’s advice, the woman did not take the CBD oil with food or hot drinks, as she wanted to avoid “feeling high”. She reported decreased appetite when taking CBD oil.
The woman did not change her diet, lifestyle or prescribed medications during this time. She also stated that she continued to smoke one pack of cigarettes per week during the monitoring period.
In an interview with Medical News TodayLead author Dr Kah Ling Liew from the Respiratory Department at Princess Alexandra Hospital in the UK commented:
“We certainly did not expect to see such striking tumor regression without any conventional cancer treatment and any other health or lifestyle changes. […] So far, several studies in animal models have shown conflicting results, with some cases reducing cancer cell growth and others finding an acceleration of cancer cell growth.
DTM also spoke with Dr. Jack Jacoub, medical oncologist and medical director of MemorialCare Cancer Institute at Orange Coast Medical Center in Fountain Valley, California.
Dr Jacoub, who was not involved in the study, said: “It certainly raises speculation, and more research is needed before it becomes a recommended drug. [treatment] option for cancer patients. From the perspective of the strength of scientific evidence, a case report is about the weakest strength, and so you should consider what you read in that context.
He stressed the need for randomized controlled clinical trials to confirm the safety and effectiveness of CBD oil for treating cancer. Dr. Jacoub explained: “You enroll patients [meeting preset criteria] and see what happens to their disease, progression-free survival, and all the typical parameters of oncology trials. That is to say […] the only way i could see [CBD oil] be mainstream [treatment].”
Dr Liew added: “The optimal dosage, form, route of administration and combination of CBD/THC for each specific type of cancer (brain, lung, liver, prostate, etc.) should be discussed. further research and be determined. There will not be one treatment that works for every form of cancer.
Dr Liew said DTM“Future studies should be aware of potential ingredient inconsistencies between CBD oils and ensure […] when replicating studies, identical components are used.
Dr Liew continued: “Clinicians should be aware that their patients may be taking unconventional and unauthorized treatments without their knowledge. It is always important to consider a patient’s choices when discussing treatment options, which means being open and honest about the potential benefits and side effects of treatments.